Eva Garland Consulting’s unique expertise in science and finance has supported innovators in leveraging over $2 billion in funding for transformative technologies.
Trending
Upcoming Webinar — SBIR/STTR Accounting & Compliance Essentials
Navigating the accounting and compliance requirements of an SBIR/STTR award can feel overwhelming. Are you prepared to manage them effectively? Join EGC’s Director of Accounting & Compliance, Aron Josefsberg, MBA, for a practical discussion on navigating SBIR/STTR accounting and compliance requirements, including common challenges new awardees face and best practices for maintaining compliance throughout the award period.
EGC Reception — The Future of Non-Dilutive Funding in an AI World
Join EGC at BIO Week in San Diego for a reception and executive briefing by Dr. Eva Garland. Attendees will gain a clear view of how AI is impacting competitive positioning and proposal strategy, along with practical insights to strengthen funding and growth strategies.
Read Now — Five Tax Mistakes that Could Put Your SBIR/STTR Company At-Risk
Get practical guidance from EGC Tax Manager PJ Donohue, CPA, on avoiding common tax mistakes that can put SBIR/STTR-funded companies at risk. In this blog, PJ highlights five costly tax and compliance missteps frequently made by award recipients and shares actionable strategies to help businesses maintain compliance, strengthen financial management practices, and protect their funding success.
EGC's June Newsletter
This month, EGC highlights client DataJoint’s $5.9M NIH funding success to advance AI-powered scientific research infrastructure. We also share opportunities to connect with our team at BIO International Convention in San Diego, feature a new blog on navigating NIH Just-in-Time (JIT) requests, and spotlight upcoming funding opportunities from ARPA-H, BARDA, NIH, NASA, and the SBA.
Watch Now — SBIR/STTR Reauthorization: What's Changed and How to Prepare
EGC’s Dr. Kelsey McLaughlin shares insights on the latest SBIR/STTR reauthorization updates and what they mean for small businesses pursuing non-dilutive funding.
Read Now — The Latest on SBIR Reauthorization
S. 3971 has been signed into law. This reauthorizes the S. 3971 is now law, officially reauthorizing the SBIR/STTR programs through 2031. Our experts have gathered the latest insights—including agency updates, new regulations, and practical guidance to help you prepare for what’s ahead.
Read Now — The NIH JIT Process: What to Expect and How to Prepare for Funding
If you’ve received a Just-in-Time (JIT) request from the National Institutes of Health (NIH), you’re one step closer to funding—but what comes next? This guide answers the most common questions about the NIH JIT process, including requirements, timelines, and how to respond effectively.
Client Highlights
Medgene
Veterinary Diagnostics and Vaccines Company Receives USDA, NIH, and DHA Funding...
TARGAN
NSF Funding and $135M Private Investment Powers Precision Poultry Technology to Transform Global Hatcheries
PediaMetrix
NIH and NSF Funding Powers PediaMetrix's AI-Driven Pediatric Screening Platform...
Crystal Sonic
Solid Financial Foundation Propels Semiconductor Manufacturing Technology...
Minerva Lithium
Minerva Lithium’s Funding Strategy Advances Its Vision for a More Sustainable Energy Supply
DataJoint
A Strategic Funding Roadmap Propels DataJoint’s Leadership in Scientific Workflows...
Ship of Theseus
Rebuilding the Body from Within, Fueled through NIH Funding...
Our Clients Have Secured
$1,991,689,721
In Non-dilutive Funding
“Our team from EGC has been extremely prompt, professional, and knowledgeable. We were considering hiring a part time administrator to help with grants management and book-keeping, but EGC has been able to provide that service with more expertise, and they do so more efficiently. I highly recommend them!”
Brian Lawson, Co-Founder
“Our company exists today because of EGC. As cost intensive as biotech is, and reticent it is to fund new science (unchartered), we’ve had to rely on any and every resource available to keep WinSanTor alive. We are now about to enter phase 3 as the first and only company regrowing and repairing peripheral nerve damage (aka peripheral neuropathy), and Eva and her team were there every step of the way. They helped us turn over every rock, and with their help, we’ve received tens of millions of dollars of funding that literally kept the company afloat. They have an amazing team, which we now consider part of our own company as far as desire and commitment.”
Stanley Kim, Co-Founder & CEO
“Working with EGC team has been critical in identifying and applying for non-dilutive grant opportunities. The team has done all the heavy lifting while helping to navigate the application process, optimizing the project rationales and providing all the help we need to navigate towards success. I would highly recommend the EGC work if you are looking to submit successful applications across all relevant funding bodies.”
Mitch Raponi, Co-Founder & CEO
“I have used EGC for 4 years now and I continue to be impressed with their team and the product offerings that come with their engagements. We began using some of their grant budget consulting this year and I am so impressed!”
Alli Truttmann, CEO
“Lu Lu has been a pleasure to work with. She is insightful and understood our technology and business plans well. I think she’s drafted an excellent strategic plan for us to pursue non-dilutive funding opportunities.”
Michael Emanuel, Founder & CEO
“I have the utmost respect for the professionalism and hard work displayed by my team at EGC. They are fantastic!”
































































